References in EGF-A peptides: A promising strategy for PCSK9 inhibition - Atherosclerosis
Statins, PCSK9 agents, and Inclisiran | Cardiometabolic CE
NEJM 在Twitter 上："Perspective: Oligonucleotide Therapeutics (image: Inclisiran Chemical Configuration and Mechanism of Action) https://t.co/M5N3RBrKZa https://t.co/hTbXXUS0n2" / Twitter
Moving Targets | Arteriosclerosis, Thrombosis, and Vascular Biology
Mechanism of action of inclisiran in conjunction with the action of PCSK9. | Download Scientific Diagram
Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges - Nishikido - 2021 - British Journal of Pharmacology - Wiley Online Library
Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges - Nishikido - 2021 - British Journal of Pharmacology - Wiley Online Library
Inclisiran (Leqvio)
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? | Journal of the American College of Cardiology
New opportunity for cholesterol lowering: inclisiran
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. | Semantic Scholar
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9 | Semantic Scholar
siRNA drug Leqvio (inclisiran) to lower cholesterol: Trends in Pharmacological Sciences
A New Approach to PCSK9 Therapeutics | Circulation Research
Therapeutic siRNA: state of the art | Signal Transduction and Targeted Therapy
Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9 - American Journal of Cardiology
Leqvio (inclisiran) for the Treatment of Hypercholaesterolemia
Inclisiran: mechanism of action. Inclisiran is a long-acting, synthetic... | Download Scientific Diagram
Inclisiran ORION Program Update Dr David Kallend Previously
Inclisiran: mechanism of action. Inclisiran is a long-acting, synthetic... | Download Scientific Diagram
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4 | Journal of the American College of Cardiology
